FREE Top 5 ASX Stocks for November 2026 Download Free Report
ASX 200

Sonic Healthcare shares jump 6% after AGM - what the FY27 guidance means for investors

(Image source: Canva)
Team Veye   November 20, 2026

Sonic Healthcare price rises by 6% since its 2026 AGM, supported by an impressive trading update and a growth driven outlook.

Best performing stocks

Sonic Healthcare Limited (ASX: SHL) is one of the leading healthcare ASX stocks, which is currently trading at a market capitalisation of $10.54 billion and a current annual partly franked dividend yield of 5.06%.

2026 AGM and presentation

SHL released its 2026 AGM presentation and chairman’s address on 19 November 2026. FY26 revenue increased by 13% year on year to $10.9 billion, led by organic revenue growth of 5%.

EBITDA grew by 11% year on year to $1.9 billion, and net profit increased by 17% year on year to $621 million. Earnings per share increased by 14% year on year to 125.6 cents per share. It has reported a return on invested capital of 6.5%, up 60 bps year on year.

Net interest bearing debt increased to $3.07 billion due to acquisitions of LADR and Cairo Diagnostics, partially offset by proceeds of sale and leaseback. It has reported a gearing ratio of 25.9% and an interest coverage ratio of 10.0x. Sonic Healthcare has distributed a total partly franked dividend yield of $1.08 per share.

FY27 updates

The organic revenue growth YTD October on a constant currency basis is in line with the expectation of 4.4%. It has continued the momentum in key growth areas including advanced diagnostics, direct to consumer testing and specialist referrals. SHL is able to achieve margin expansion as per expectations. German and Swiss synergy realisation is progressing as planned. The US operating review is ongoing and is expected to plan specific initiatives tracking. The potential PAMA impact for FY2027, updated to $24 million based on the recent draft CMS fee schedule, remains uncertain that changes will occur.

FY2027 guidance update

SHL is optimistic as it looks to continue to pursue growth opportunities with medical and financial discipline. It is expected to unlock significant potential and convert it into stronger earnings, improved returns and long term shareholder value. SHL is focused on growing its customer base via improved digital access and new channels. SHL is expected to develop precision and personalized healthcare, including advanced diagnostics. SHL expects to increase capacity cost and decrease cost by scaling automation, robotics and AI. FY27 EBITDA is expected to be between $1.95-$2.03 billion excluding $30 million of back office IT systems transformation costs.

Conclusion

SHL price rally is based on impressive FY27 update and long term outlook. SHL is looking to grow its revenue stream, but is also implementing cost reduction measures such as automation and AI integration. It will allow the company to have both long-term revenue and earnings growth. SHL’s long term vision and FY27 update has boosted investor’s confidence on its ability to create long term value. SHL has a trailing 12 months of EV/sales of 1.39x, which is below the industry median of 1.60x. SHL has a consistent history of paying dividends and investors will be rewarded with its current annual partly franked dividend yield of 5.06%.

(Source: Company Announcements)

Unlock Full Article

Enter your details to continue reading

Get your Free Report on Top 5 ASX stocks for 2026
💬

Get Your Free Report on Top 5 ASX Stocks on WhatsApp

Instant Access. No Credit Card Required.

Receive on WhatsApp

TOP ASX STOCKS WORTH WATCHTING

  • ✓ Instant Access
  • ✓ No Credit Card Required
  • ✓ Free to join · No spam
Get Free Report on WhatsApp

Free to join · No spam · Unsubscribe anytime

By providing your details, you agree to Veye's Terms & Conditions, Privacy Policy, and Financial Services Guide and to receive marketing offers. Before you access our services, please read the Financial Services Guide available here.

EXCLUSIVE OFFER

7 day free trial

Start Free Trial
7‑day free trial

ASX Stock Research & Recommendations — 7‑day free trial

Independent, analyst‑driven insights.

  • Stock of the week report
  • Daily Analysis Report
  • No credit card required
General information only. Not financial advice.

Get Your FREE Report

Discover the Top ASX Stocks to Invest In 2026!

Expert Analysis of Top-Performing ASX Stocks

Market Insights and In-Depth Research

Buy, Sell, And Hold Recommendations

Almost There!

Enter your details to download the report

Success!

Preparing your download...

Disclaimer

Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.